Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CNTN NASDAQ:EDSA NASDAQ:JMAC NASDAQ:TNXP On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCNTNHillstream Biopharma$3.09+2.3%$3.19$1.08▼$9.08$210.81M1.41783,632 shs777,252 shsEDSAEdesa Biotech$5.80+2.7%$9.12$0.72▼$20.32$50.24M1.03344,974 shs174,979 shsJMACMaxpro Capital Acquisition$13.70-0.7%$14.23$7.50▼$19.22$183.96M0.0174,040 shs8,880 shsTNXPTonix Pharmaceuticals$11.35+6.6%$13.04$10.03▼$69.97$169.77M1.67531,445 shs675,921 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Click the link to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCNTNHillstream Biopharma+2.37%+23.27%-7.65%-25.80%+301,999,900.00%EDSAEdesa Biotech+8.77%-20.07%-57.29%-4.92%+204.68%JMACMaxpro Capital Acquisition-3.57%-0.93%-10.74%-30.35%+112.15%TNXPTonix Pharmaceuticals-2.83%-10.35%-19.80%-19.56%-71.76%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCNTNHillstream Biopharma$3.09+2.3%$3.19$1.08▼$9.08$210.81M1.41783,632 shs777,252 shsEDSAEdesa Biotech$5.80+2.7%$9.12$0.72▼$20.32$50.24M1.03344,974 shs174,979 shsJMACMaxpro Capital Acquisition$13.70-0.7%$14.23$7.50▼$19.22$183.96M0.0174,040 shs8,880 shsTNXPTonix Pharmaceuticals$11.35+6.6%$13.04$10.03▼$69.97$169.77M1.67531,445 shs675,921 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Click the link to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCNTNHillstream Biopharma+2.37%+23.27%-7.65%-25.80%+301,999,900.00%EDSAEdesa Biotech+8.77%-20.07%-57.29%-4.92%+204.68%JMACMaxpro Capital Acquisition-3.57%-0.93%-10.74%-30.35%+112.15%TNXPTonix Pharmaceuticals-2.83%-10.35%-19.80%-19.56%-71.76%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCNTNHillstream Biopharma 1.00SellN/AN/AEDSAEdesa Biotech 2.00Hold$5.00-13.79% DownsideJMACMaxpro Capital Acquisition 0.00N/AN/AN/ATNXPTonix Pharmaceuticals 2.50Moderate Buy$22.0093.83% UpsideCurrent Analyst Ratings BreakdownLatest EDSA, JMAC, TNXP, and CNTN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/3/2026CNTNHillstream Biopharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/15/2026CNTNHillstream Biopharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/5/2026TNXPTonix Pharmaceuticals TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy5/4/2026TNXPTonix Pharmaceuticals TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$22.004/20/2026TNXPTonix Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)3/27/2026EDSAEdesa Biotech Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)(Data available from 6/12/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCNTNHillstream BiopharmaN/AN/AN/AN/A$10.92 per shareN/AEDSAEdesa BiotechN/AN/AN/AN/A$0.45 per shareN/AJMACMaxpro Capital AcquisitionN/AN/AN/AN/AN/AN/ATNXPTonix Pharmaceuticals$17.56M10.31N/AN/A$19.17 per share0.59Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCNTNHillstream Biopharma-$35.92M-$1.15N/AN/AN/AN/A-31.50%-24.72%N/AEDSAEdesa Biotech-$7.19M-$1.34N/AN/AN/AN/A-286.52%-75.36%8/14/2026 (Estimated)JMACMaxpro Capital AcquisitionN/AN/AN/AN/AN/AN/AN/AN/AN/ATNXPTonix Pharmaceuticals-$124.02M-$14.36N/AN/AN/A-839.52%-67.65%-60.47%8/10/2026 (Estimated)Latest EDSA, JMAC, TNXP, and CNTN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2026Q2 2026EDSAEdesa Biotech-$0.24-$0.49-$0.25-$0.49$0.05 millionN/A5/13/2026Q1 2026CNTNHillstream BiopharmaN/A-$0.23N/A-$0.23N/AN/A5/11/2026Q1 2026TNXPTonix Pharmaceuticals-$2.54-$2.93-$0.39-$2.93$6.13 million$6.88 million3/31/2026Q4 2025CNTNHillstream BiopharmaN/A$0.54N/A$0.54N/AN/A3/12/2026Q4 2025TNXPTonix Pharmaceuticals-$3.16-$3.98-$0.82-$3.98$2.97 million$5.39 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCNTNHillstream BiopharmaN/AN/AN/AN/AN/AEDSAEdesa BiotechN/AN/AN/AN/AN/AJMACMaxpro Capital AcquisitionN/AN/AN/AN/AN/ATNXPTonix PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCNTNHillstream BiopharmaN/A37.7637.76EDSAEdesa BiotechN/A4.764.76JMACMaxpro Capital AcquisitionN/AN/AN/ATNXPTonix PharmaceuticalsN/A6.996.86Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCNTNHillstream Biopharma1.16%EDSAEdesa Biotech5.50%JMACMaxpro Capital Acquisition73.18%TNXPTonix Pharmaceuticals82.26%Insider OwnershipCompanyInsider OwnershipCNTNHillstream Biopharma6.70%EDSAEdesa Biotech24.40%JMACMaxpro Capital Acquisition19.27%TNXPTonix Pharmaceuticals2.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCNTNHillstream Biopharma269.81 million65.13 millionN/AEDSAEdesa Biotech208.89 million6.72 millionNot OptionableJMACMaxpro Capital Acquisition2,02113.43 million10.84 millionNot OptionableTNXPTonix Pharmaceuticals5015.94 million15.62 millionNot OptionableEDSA, JMAC, TNXP, and CNTN HeadlinesRecent News About These CompaniesTonix Pharmaceuticals to Attend BTIG Infectious Disease Day 2026June 11 at 9:24 AM | finance.yahoo.comTonix Pharmaceuticals to Attend BTIG Infectious Disease Day 2026June 11 at 7:00 AM | globenewswire.comTonix Pharmaceuticals (NASDAQ:TNXP) Director Richard Newcomb Stillwell Purchases 5,000 SharesJune 10 at 6:10 AM | insidertrades.comWhy Is TNXP Stock Rising Today?June 8, 2026 | stocktwits.comSTonix Shares Jump After Landing Second Commercial Payer Agreement For TONMYAJune 8, 2026 | benzinga.comTonix Shares Jump After Landing Second Commercial Payer Agreement For TONMYAJune 8, 2026 | benzinga.comTonix Pharmaceuticals Secures Second Commercial Payer Agreement for TONMYA®, Expanding Total Commercial Coverage to ~52 Million U.S. LivesJune 8, 2026 | finance.yahoo.comTonix Pharmaceuticals Secures Second Commercial Payer Agreement for TONMYA®, Expanding Total Commercial Coverage to ~52 Million U.S. LivesJune 8, 2026 | globenewswire.comTonix Advances TNX-102 SL Into Phase 2 Depression Trial, Drawing Investor FocusJune 2, 2026 | tipranks.comTonix Pharmaceuticals Presented Retrospective U.S. Real-World Claims Analysis of Opioid Use in Patients with Fibromyalgia at the 2026 American Society of Clinical ...May 29, 2026 | markets.businessinsider.comTonix Pharmaceuticals Presented Retrospective U.S. Real-World Claims Analysis of Opioid Use in Patients with Fibromyalgia at the 2026 American Society of Clinical Psychopharmacology (ASCP) Annual MeetingMay 28, 2026 | finance.yahoo.comTonix Pharmaceuticals Presented Retrospective U.S. Real-World Claims Analysis of Opioid Use in Patients with Fibromyalgia at the 2026 American Society of Clinical Psychopharmacology (ASCP) Annual MeetingMay 28, 2026 | globenewswire.comAnalysts Offer Insights on Healthcare Companies: Daxor (DXR) and Tonix Pharma (TNXP)May 27, 2026 | theglobeandmail.comTonix Pharmaceuticals Announces Publication of Phase 1 Clinical Data of TNX-1500, an Fc-Modified anti-CD40L (CD154) Monoclonal Antibody, in the Peer-Reviewed Journal of ...May 27, 2026 | markets.businessinsider.comTonix Pharmaceuticals Announces Publication of Phase 1 Clinical Data of TNX-1500, an Fc-Modified anti-CD40L (CD154) Monoclonal Antibody, in the Peer-Reviewed Journal of Clinical ImmunologyMay 27, 2026 | finance.yahoo.comTonix Pharma Highlights Positive Phase 1 TNX-1500 ResultsMay 27, 2026 | tipranks.comTonix Pharmaceuticals Announces Publication of Phase 1 Clinical Data of TNX-1500, an Fc-Modified anti-CD40L (CD154) Monoclonal Antibody, in the Peer-Reviewed Journal of Clinical ImmunologyMay 27, 2026 | globenewswire.comTonix Pharmaceuticals Presented Retrospective U.S. Real-World Claims Analysis Characterizing Patients with Fibromyalgia at The Professional Society for Health Economics and ...May 26, 2026 | markets.businessinsider.comTonix Pharmaceuticals Presented Retrospective U.S. Real-World Claims Analysis Characterizing Patients with Fibromyalgia at The Professional Society for Health Economics and Outcomes Research (ISPOR) 2026 Annual MeetingMay 26, 2026 | finance.yahoo.comTonix Pharmaceuticals Presented Retrospective U.S. Real-World Claims Analysis Characterizing Patients with Fibromyalgia at The Professional Society for Health Economics and Outcomes Research (ISPOR) 2026 Annual MeetingMay 26, 2026 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeEDSA, JMAC, TNXP, and CNTN Company DescriptionsHillstream Biopharma NASDAQ:CNTN$3.09 +0.07 (+2.32%) Closing price 04:00 PM EasternExtended Trading$3.06 -0.03 (-1.13%) As of 07:02 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Hillstream BioPharma, Inc., a pre-clinical biotechnology company, develops novel therapeutic candidates targeting ferroptosis, an anti-cancer mechanism resulting in iron mediated cell death (IMCD) for the treatment resistant cancers. The company's product candidate is HSB-1216, an IMCD inducer targeting solid tumors. It also develops HSB-888, a dual Quatramer loaded IMCD inducer coupled with its anthracycline analogue for solid tumors; HSB-510, a targeted bifunctional inhibitory compound in Quatramer with single digit nanomolar; IC50 against PI3K-delta and HDAC6, which is also known to downregulate; c-myc, a cancer drug target; and HSB-114, an immunotherapeutic agent, which uses its Quatramer technology to deliver tumor necrosis factor-alpha gene into cancer cells. The company was incorporated in 2019 and is based in Bridgewater, New Jersey.Edesa Biotech NASDAQ:EDSA$5.80 +0.15 (+2.65%) Closing price 04:00 PM EasternExtended Trading$5.90 +0.11 (+1.81%) As of 07:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in Covid-19 patients; and EB01, a topical vanishing cream containing non-steroidal anti-inflammatory compound that has completed Phase 2b clinical study to treat chronic allergic contact dermatitis. The company also develops EB02, an extension of secretory phospholipase 2 anti-inflammatory cream for treating erythema, swelling, and exudation associated with hemorrhoids disease; and EB06, an anti- chemokine ligand 10 (CXCL10) monoclonal antibody in vitiligo. It has a collaboration agreement with NovImmune SA to develop monoclonal antibodies targeting products containing toll-like receptor 4 and CXCL10 for therapeutic, prophylactic, and diagnostic applications in humans and animals; and Yissum Research Development Company for the development of products for therapeutic, prophylactic, and diagnostic uses in topical dermal and anorectal applications, as well as for the use in dermatologic and gastrointestinal conditions. The company was founded in 2015 and is headquartered in Markham, Canada.Maxpro Capital Acquisition NASDAQ:JMAC$13.70 -0.09 (-0.65%) As of 06/11/2026Maxpro Capital Acquisition Corp. does not have significant operations. It intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was incorporated in 2021 and is based in Taipei City, Taiwan.Tonix Pharmaceuticals NASDAQ:TNXP$11.35 +0.70 (+6.57%) Closing price 04:00 PM EasternExtended Trading$11.15 -0.20 (-1.76%) As of 07:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults. Its portfolio focuses on central nervous system disorders, as well as rare disease, immunology, and infectious disease product candidates. The company's priority is to submit a New Drug Application (NDA) to the FDA for TNX-102 SL (cyclobenzaprine HCl sublingual tablet), which has completed two positive Phase 3 studies for the management of fibromyalgia. TNX-102 SL is also being developed to treat fibromyalgia-type Long COVID, a chronic post-acute COVID-19 condition. Its TNX-1300 (cocaine esterase) is a biologic designed to treat cocaine intoxication and has been granted breakthrough therapy designation by the FDA. The company's rare disease development portfolio comprises TNX-2900, an intranasal potentiated oxytocin for the treatment of Prader-Willi syndrome (PWS). Its immunology portfolio includes TNX-1500, which is a biologic to address organ transplant rejection and autoimmune diseases. The company's infectious disease pipeline includes TNX-801, a vaccine in development to prevent smallpox and mpox. TNX-801 also serves as the live virus vaccine platform or recombinant pox vaccine platform for other infectious diseases, including TNX-1800 and TNX-1850, in development as a vaccine to protect against COVID-19. Its infectious disease development portfolio also comprises TNX-3900, and TNX-4200 are orally available CD45 antagonists in preclinical development. Tonix Pharmaceuticals Holding Corp. has collaboration agreement with Bilthoven Biologicals to advance TNX-801 mpox vaccine candidate; and with X-Chem, Inc. to develop broad-spectrum antivirals. The company was founded in 2007 and is headquartered in Chatham, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas SpaceX Rings the Bell and Shatters Every Record Adobe Stock Just Got Cheaper—Is Wall Street Missing the Story? ERock IPO: A $1.3B Power Play Solution Boeing’s Unseen Rebound: Why the Headlines Are Wrong Why Oracle's 10% Drop May Be Telling the Wrong Story Spotify's "North Star" Outlook Was Music to Investors Ears DraftKings Hits the Jackpot With Super App Pivot Cracker Barrel Surges 23% as Earnings Beat Signals Turnaround Progress Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
